Kanjinti 150 mg
Kanjinti 150 mg is a medicine authorised by Swissmedic under authorisation number 67205. The authorisation holder is Amgen Switzerland AG. The medicinal product code is Biotechnological medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 11 November 2019 and the authorisation is valid without a time limit. ATC code L01FD01 places the medicine in the group Antineoplastic agents.
| Authorisation number | 67205 |
|---|---|
| Name | Kanjinti 150 mg |
| Full name | Kanjinti 150 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung |
| Authorisation holder | Amgen Switzerland AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01FD01 |
| First authorisation | 11 November 2019 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Kanjinti 150 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung | A | 11 November 2019 |
| 2 | Kanjinti 440 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung | A | 11 November 2019 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Durchstechflasche(n) | L01FD01 | 07.16.1. | A |
| 2 | 1 | Durchstechflasche(n) | L01FD01 | 07.16.1. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Kanjinti 150 mg authorised in Switzerland?
Yes. Kanjinti 150 mg is authorised by Swissmedic under authorisation number 67205, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Kanjinti 150 mg have?
Kanjinti 150 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Kanjinti 150 mg?
The authorisation holder is Amgen Switzerland AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.